2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Cell Expansion, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Women’s Health, Adverse Events, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

4267 A multicenter pilot trial of olutasidenib as maintenance after allogeneic hematopoietic cell transplantation (alloHCT) IDH1-mutated AML/MDS

Amandeep Salhotra, MD, Dongyun Yang, PhD2, Sally Mokhtari, PhD3, Abhay Singh, MD, MPH4, Claudio Brunstein, MD, PhD5, Brian John Ball, MD, MS6, Salman Otoukesh, MD7, Firoozeh Sahebi8, Nahid Rashid, MD9, Ji-Lian Cai, MD, PhD10, Haris Ali, MD11, Karamjeet Singh Sandhu, MD12, Vaibhav Agrawal, MD13, Ling Li, PhD14, Guido Marcucci, MD15, Ryotaro Nakamura, MD16
1 City of Hope, Duarte, California, United States
2 City of Hope, Duarte, California, United States
3 City of Hope, Duarte, California, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 City of Hope, Duarte, California, United States
7 City of Hope, Duarte, California, United States
8 City of Hope, Duarte, California, United States
9 City of Hope, Duarte, California, United States
10 City of Hope, Duarte, California, United States
11 City of Hope, Duarte, California, United States
12 City of Hope, Duarte, California, United States
13 City of Hope, Duarte, California, United States
14 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
15 City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States, City of Hope, Duarte, California, United States
16 City of Hope, Duarte, California, United States

Somatic mutations in isocitrate dehydrogenase 1 (IDH1) occur in ~10% of patients with AML and 3-5% of patients with MDS. We and others have previously reported an increased risk of relapse after alloHCT among patients with IDH-mutated disease, supporting the need for effective post-HCT maintenance strategies. Olutasidenib, an oral small-molecule inhibitor of mutant IDH1 (mIDH1) has shown clinical activity in relapse/refractory IDH1-mutated AML with an overall response rate (ORR) of 48% and durable response in patients achieving complete remission (CR)/CR with incomplete hematopoietic recovery (CRh). Here, we report results from our multicenter pilot trial evaluating Olutasidenib as post-HCT maintenance in IDH1-mutated AML/MDS (NCT06543381).

Adults with IDH1-mutated AML, or MDS undergoing alloHCT were eligible if they achieved morphologic remission by day +30 post-HCT and had adequate marrow function. MRD positivity either by flow cytometry or IDH1 mutation testing by NGS; and prior IDH1 inhibitor exposure were permitted. Olutasidenib was administered at the FDA-approved dose of 150 mg twice daily within days +50 to +120 post-HCT and continued for 2 years. The primary objective was safety and tolerability, with survival and GVHD outcomes as secondary objectives. The target sample size is 15 patients, with early stopping guided by a modified Pocock-boundary toxicity-monitoring rule of toxicity-monitoring if the unacceptable toxicity rate was ≥33%.

Between 2024-2025, 9 patients (n=7 AML and n=2 MDS) were enrolled at City of Hope; the trial has recently opened at Cleveland Clinic. The median age was 64 years (range 42-71) and most patients were Caucasian (78%). All AML patients were in CR1 pre-HCT, and 6 of 7 (85%) were MRD negative. AML patients had ELN 2022 adverse (n=3; 43%) or intermediate (n=4; 57%) -risk disease, and both MDS patients had high-risk disease by IPSS. Most patients received reduced intensity conditioning (n=6; 66%), PBSC was the graft source. Patients received HCT from 8/8 HLA matched (n=4; 66%) or 7/8 mismatched unrelated donor (n=2; 33%). Post-transplant cyclophosphamide GVHD prophylaxis was used in 6 patients (66%), one patient received T cell-depleted graft and 2 received CNI-based prophylaxis.

At abstract submission, 6 of the 9 enrolled patients remained on the study with median number of cycles of olutasidenib of 7 cycles (range 1-21); three patients have been receiving olutasidenib for more than 1 year. Reasons for discontinuation were death from fungal pneumonia (unrelated to olutasidenib at day +131 of post-HCT maintenance), MRD relapse after one year of treatment, and withdrawal for personal reasons at day +7 (n=1 each). Median time to olutasidenib initiation was 119 days from HCT (range 77-160; two patients started olutasidenib after day +120 due to cytopenia). No DLT has been noted so far. AEs of all grades were collected during cycles 1-2, whereas only grade ≥3 AEs were collected from cycle 3 onward. During cycles 1-2, grade ≥3 hematologic AEs included anemia (n=1) and lymphopenia (n=2). Grade 3 non-hematologic AEs included gastrointestinal disorder, nausea, starvation ketosis, AKI, dehydration, and dyspnea (n=1 each), and one grade 4 acidosis. From cycle 3 onward, grade ≥3 AEs were largely similar, with one grade 4 metabolic acidosis reported.

At the median follow-up duration of 6.9 months (range 0.2-18.3), one-year OS and LFS were 83% (95% CI: 0.27-0.97) and 63% (95% CI: 0.14-0.89), respectively. Cumulative incidence of acute GVHD grade 2-4 at day 100 and 180 were 17% (95%CI: 0.005-0.55), and none of the patients developed chronic GVHD.  

In conclusion, post-HCT olutasidenib maintenance appears feasible and well-tolerated in this early analysis, with no unexpected safety signals observed to date. Ongoing multicenter accrual will further characterize safety, tolerability, and preliminary efficacy in patients with IDH1-mutated AML/MDS.

Amandeep Salhotra, MD: Sobi - Research Funding; Incyte - Research Funding; Rigel - Research Funding; Bristol-Myers Squibb - Research Funding; OrcaBio - Research Funding; Jazz Pharma - Research Funding; Pierview - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony)